| Title |
A spectrum of cutaneous toxicities from erlotinib may be a robust clinical marker for non-small-cell lung therapy: a case report and literature review
|
|---|---|
| Published in |
OncoTargets and therapy, April 2015
|
| DOI | 10.2147/ott.s83888 |
| Pubmed ID | |
| Authors |
Feng Jin, Hui Zhu, Li Kong, Jinming Yu |
| Abstract |
Some literature suggests that an EGFR inhibition-induced rash can be used as a clinical marker, but few studies report the correlation between a spectrum of cutaneous toxicities from EGFR inhibition and drug efficacy. We report about a woman with a stage IV lung adenocarcinoma using erlotinib monotherapy, who experienced a spectrum of cutaneous toxicities, including papulopustular rash, mucositis, pruritus, xerosis, paronychia, and facial hirsutism. With treatment, her metastatic lesions shrunk remarkably. This report suggests that some non-small-cell lung cancer patients experiencing a spectrum of cutaneous toxicities might have a good tumor response using erlotinib monotherapy. Our findings may provide a method for clinicians to predict erlotinib efficacy in non-small-cell lung cancer therapy without knowledge of the EGFR mutation status. |
Mendeley readers
The data shown below were compiled from readership statistics for 11 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 11 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Other | 2 | 18% |
| Researcher | 2 | 18% |
| Student > Master | 2 | 18% |
| Professor | 1 | 9% |
| Student > Bachelor | 1 | 9% |
| Other | 1 | 9% |
| Unknown | 2 | 18% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 5 | 45% |
| Biochemistry, Genetics and Molecular Biology | 2 | 18% |
| Immunology and Microbiology | 1 | 9% |
| Pharmacology, Toxicology and Pharmaceutical Science | 1 | 9% |
| Unknown | 2 | 18% |
Attention Score in Context
This research output has an Altmetric Attention Score of 7. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 21 May 2015.
All research outputs
#4,963,567
of 25,870,940 outputs
Outputs from OncoTargets and therapy
#223
of 3,017 outputs
Outputs of similar age
#57,369
of 280,116 outputs
Outputs of similar age from OncoTargets and therapy
#4
of 37 outputs
Altmetric has tracked 25,870,940 research outputs across all sources so far. Compared to these this one has done well and is in the 79th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 3,017 research outputs from this source. They receive a mean Attention Score of 3.0. This one has done particularly well, scoring higher than 91% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 280,116 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 78% of its contemporaries.
We're also able to compare this research output to 37 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 86% of its contemporaries.